Authorized purpose: The K231190 EPIQ submission adds the mL26-8 linear-array transducer for high-resolution superficial imaging, including labeled musculoskeletal, ophthalmic, pediatric, peripheral-vessel, breast, thyroid, and testicular applications, within the EPIQ diagnostic ultrasound system workflow.
Clinical role
Ultrasound acquisition, measurement, analysis, reporting, and release-specific AI assistance.
Images and patients
Ultrasound · Multi-region
Key limitation
Keep in mind: AI-assisted measurements, views, and guidance do not replace image-quality assessment or clinician interpretation; supported probes, host devices, populations, and features differ by release.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: The K231190 EPIQ submission adds the mL26-8 linear-array transducer for high-resolution superficial imaging, including labeled musculoskeletal, ophthalmic, pediatric, peripheral-vessel, breast, thyroid, and testicular applications, within the EPIQ diagnostic ultrasound system workflow.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Multi-region Input: Live or imported ultrasound data from supported probes, systems, host devices, and applications.
Who uses it?Intended users: Qualified physicians, sonographers, and other trained ultrasound professionals.
What does the software produce?Output: Ultrasound images, measurements, calculations, overlays, and reports for clinician review.
What is its most important limitation?Key limitation: AI-assisted measurements, views, and guidance do not replace image-quality assessment or clinician interpretation; supported probes, host devices, populations, and features differ by release.
Clinical takeaway. Clinical role: The K231190 EPIQ submission adds the mL26-8 linear-array transducer for high-resolution superficial imaging, including labeled musculoskeletal, ophthalmic, pediatric, peripheral-vessel, breast, thyroid, and testicular applications, within the EPIQ diagnostic ultrasound system workflow.
Evidence takeaway. Evidence from the reviewed source record: The K231190 FDA decision summary documents the mL26-8 transducer addition, its frequency range and superficial high-resolution applications, and the unchanged EPIQ diagnostic-ultrasound indications. The FDA package does not establish a general AI diagnostic sensitivity or specificity claim.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
The K231190 EPIQ submission adds the mL26-8 linear-array transducer for high-resolution superficial imaging, including labeled musculoskeletal, ophthalmic, pediatric, peripheral-vessel, breast, thyroid, and testicular applications, within the EPIQ diagnostic ultrasound system workflow.
AI-assisted measurements, views, and guidance do not replace image-quality assessment or clinician interpretation; supported probes, host devices, populations, and features differ by release.
The K231190 FDA decision summary documents the mL26-8 transducer addition, its frequency range and superficial high-resolution applications, and the unchanged EPIQ diagnostic-ultrasound indications. The FDA package does not establish a general AI diagnostic sensitivity or specificity claim.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The K231190 FDA decision summary documents the mL26-8 transducer addition, its frequency range and superficial high-resolution applications, and the unchanged EPIQ diagnostic-ultrasound indications. The FDA package does not establish a general AI diagnostic sensitivity or specificity claim.
Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-03
Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K231190 FDA performance package for EPIQ Series Diagnostic Ultrasound System
DesignManufacturer transducer, acoustic, image-quality, software, electrical-safety, EMC, and usability verification and validation submitted in K231190
PopulationEPIQ examinations using the mL26-8 linear-array transducer for labeled superficial, ophthalmic, pediatric, vascular, and small-organ applications
Scopeexact submission
Tested versionEPIQ Ultrasound Diagnostic System with mL26-8 transducer (K231190)
IndependenceSponsor or vendor study
K231190
Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
4 exact-submission FDA recall records in the 2026-09-02 openFDA snapshot identify K231190. Affected model, version, unit, correction, and current manufacturer instructions still require local confirmation. FDA recall Z-2386-2025 is Open, Classified for mL26-8 Transducer Probe. FDA reason: To provide clarification and labelling to define the useful life of ultrasound transducers in the field. FDA action: An URGENT Medical Device Correction Notice, dated 7/3/25, was mailed to consignees. This notice instructs consignees to locate all Philips Ultrasound transducers in their facility and enter their serial numbers into https://www.transducer.philips.com to obtain the manufacturing certificate for each of their devices. This certificate should be retained with its system documentation. Using the manufacturing certificate consignees are to calculate the useful life of their device. The expected useful life for Transesophageal transducers, X-Matrix transducers, and Lumify transducers is 5 years; The expected useful life for Endocavity transducers and Transcutaneous transducers is 7 years. If a transducer has exceeded its useful life, consignees are instructed to conduct transducer performance tests or contact Philips for guidance. Consignees are asked to complete and return the provided response form and circulate the recall notification to device users for their awareness. Consignees with any questions can contact Philips Customer Care Solutions Center at 1-800-722-9377. FDA recall Z-0283-2024 is Completed for Philips EPIQ Diagnostic Ultrasound System Models: EPIQ 7G(model # 795200), EPIQ 7C (Model # 795201), EPIQ 7W (Model # 795202), EPIQ 5G (model # 795204), EPIQ 5W (model # 795206), EPIQ CVx (Model # 795231), EPIQ Elite (model # 795234). FDA reason: Their is the potential that diagnostic ultrasound systems operating with software version 10.0 may present a delayed image instead of a real time image. FDA action: On October 9, 2023, Philips issued a Urgent Medical Device Correction notification to affected consignees. Philips asked consignees to take the following actions: 1. Identify if your firm has an affected product. 2. In the 2D tab in the system touchscreen, disable the AutoSCAN feature every time a transducer or a Transducer preset is selected to prevent the system from potentially experiencing image lag issue. The AutoSCAN feature is disabled when the button is not highlighted in amber. 3. Please complete and return the attached response form to Philips promptly and no later than 15 days from receipt. Completing this form confirms receipt of the Urgent Medical Device Correction Letter, understanding of the issue, and required actions to be taken. 4. Circulate this Urgent Medical Device Correction Letter to all users of this device so that they are aware of the issue. Please retain this letter with your system(s) and ensure the letter is in a place likely to be seen/viewed. 5. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, or by regular mail, or by fax. FDA recall Z-0284-2024 is Completed for Philips Affiniti 70, Diagnostic Ultrasound System Model # 795210. FDA reason: Their is the potential that diagnostic ultrasound systems operating with software version 10.0 may present a delayed image instead of a real time image. FDA action: On October 9, 2023, Philips issued a Urgent Medical Device Correction notification to affected consignees. Philips asked consignees to take the following actions: 1. Identify if your firm has an affected product. 2. In the 2D tab in the system touchscreen, disable the AutoSCAN feature every time a transducer or a Transducer preset is selected to prevent the system from potentially experiencing image lag issue. The AutoSCAN feature is disabled when the button is not highlighted in amber. 3. Please complete and return the attached response form to Philips promptly and no later than 15 days from receipt. Completing this form confirms receipt of the Urgent Medical Device Correction Letter, understanding of the issue, and required actions to be taken. 4. Circulate this Urgent Medical Device Correction Letter to all users of this device so that they are aware of the issue. Please retain this letter with your system(s) and ensure the letter is in a place likely to be seen/viewed. 5. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, or by regular mail, or by fax. FDA recall Z-1007-2026 is Completed for Philips EPIQ Ultrasound Systems (various models) used in conjunction with the X5-1c transducer REF: , , 795200, 795201, 795231, 795232, 795234 REF: 795117, 795122. FDA reason: Retroactive: Ultrasound may experience an unexpected automatic reboot, resulting in damage to transducer. FDA action: On July 18, 2022, Phillips issued a product notification to affected consignees. Philips ask consignees to take the following actions: 1. If the X5-1c transducer is connected to the right-most port (when viewing from the front), this problem will not occur. Please ensure your X5-1c is connected to the right-most connector until the software update (FCO79500561) has been installed. 2. Please retain this letter with your product documentation until the software update (FCO79500561) has been implemented on your system. 3. Please circulate this notice to all users of this device so that they are aware of the issue. 4. A Philips Field Service Engineer will contact you to schedule the installation of the software update to resolve this issue (reference FCO79500561).
FDA source
Exact FDA submission
Checked 2026-09-04
Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.
Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; the FDA record does not identify an AI-algorithm defect unless it says so. Confirm affected model, version, units, corrective action, and completion status locally.
Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; the FDA record does not identify an AI-algorithm defect unless it says so. Confirm affected model, version, units, corrective action, and completion status locally.
Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; the FDA record does not identify an AI-algorithm defect unless it says so. Confirm affected model, version, units, corrective action, and completion status locally.
Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; the FDA record does not identify an AI-algorithm defect unless it says so. Confirm affected model, version, units, corrective action, and completion status locally.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Live or imported ultrasound data from supported probes, systems, host devices, and applications.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Validate supported probes and host devices, patient matching, DICOM or local export, PACS measurements, worklist, report transfer, and offline or downtime behavior.
Scope: Product family. Current vendor materials are product-family evidence for K231190; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: Ultrasound hardware or software with supported probes, host devices, licensed options, and network configuration.
Scope: Product family. Current vendor materials are product-family evidence for K231190; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Ultrasound images, measurements, calculations, overlays, and reports for clinician review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Ultrasound hardware or software with supported probes, host devices, licensed options, and network configuration.
Product family
Checked 2026-09-03
Current vendor materials are product-family evidence for K231190; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Validate supported probes and host devices, patient matching, DICOM or local export, PACS measurements, worklist, report transfer, and offline or downtime behavior.
Product family
Checked 2026-09-03
Current vendor materials are product-family evidence for K231190; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Philips' Responsible Disclosure Statement states that Philips maintains a global network of product security officers for developing and deploying security and privacy features for its products and services and for managing security events; that vulnerability reports to productsecurity@philips.com (PGP-encrypted) are acknowledged within two business days with a tracking number and an assigned contact; status updates approximately every 2-3 weeks; a 90-day resolution aim; and patch or advisory notification through existing customer notification processes. Vendor statement; no certification or test report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: the statement is on philips.com (Royal Philips) and covers Philips products and services; the FDA applicant entity appears in Philips' own BCR members list on documents.philips.com (Philips Ultrasound LLC, Philips Medical Systems Nederland B.V., Philips Healthcare (Suzhou), Philips Medical Systems DMC GmbH, Philips Medical Systems Technologies Ltd., Philips Oy). Corporate policy; exact-release scope is not established.
Only qualified physicians, sonographers, and other trained ultrasound professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: AI-assisted measurements, views, and guidance do not replace image-quality assessment or clinician interpretation; supported probes, host devices, populations, and features differ by release.
Product family
Checked 2026-09-03
Current vendor materials are product-family evidence for K231190; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Validate supported probes and host devices, patient matching, DICOM or local export, PACS measurements, worklist, report transfer, and offline or downtime behavior.
product family · checked 2026-09-03
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Vendor statements are current product-family context; confirm the exact cleared release and installed options.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. AI-assisted measurements, views, and guidance do not replace image-quality assessment or clinician interpretation; supported probes, host devices, populations, and features differ by release.
exact submission · checked 2026-09-03
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03
No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: AI-assisted measurements, views, and guidance do not replace image-quality assessment or clinician interpretation; supported probes, host devices, populations, and features differ by release.
product family · checked 2026-09-03
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Vendor statements are current product-family context; confirm the exact cleared release and installed options.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 4 FDA recall candidates were manually reviewed: 4 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 4 postmarket candidate records; 4 have been reviewed (4 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Ge Medical Systems Ultrasound and Primary Care Diagnostics
Authorized purpose: LOGIQ E10 is a general diagnostic ultrasound system for qualified users across fetal and obstetric, abdominal, gynecologic, pediatric, small-organ, breast, cardiac, vascular, musculoskeletal, urologic, transrectal, transvaginal, transesophageal, and intraoperative applications.
Butterfly iQ3 is a general-purpose portable ultrasound system for adult and pediatric imaging, peripheral vessels, small organs, breast, thyroid, scrotum, cardiac, abdominal, lung, urologic, and procedural-guidance workflows.
Authorized purpose: The Clarius Ultrasound Scanner is a software-based diagnostic ultrasound imaging system for trained healthcare professionals across labeled abdominal, thoracic, musculoskeletal, breast, thyroid, testicular, pediatric, neonatal, cardiac, vascular, transrectal, transvaginal, and procedural workflows.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.